Results 1 to 10 of about 1,726 (158)

A multifunctional drug consisting of tetracycline conjugated with odanacatib for efficient periodontitis therapy [PDF]

open access: yesFrontiers in Pharmacology, 2022
The treatment of periodontitis can be very challenging due to its complex etiologies. A new pharmacologic strategy entitled “host-modulation therapy,” has been introduced to improve periodontal treatment outcomes.
Dengke Li   +13 more
doaj   +3 more sources

Efficacy and safety of odanacatib in the treatment of postmenopausal women with osteoporosis: a meta-analysis [PDF]

open access: yesJournal of Orthopaedic Surgery and Research
Background Osteoporosis, a systemic skeletal disease, seriously affects the quality of life in postmenopausal women. As one type of cathepsin K (CatK) inhibitor, odanacatib (ODN) is a fresh medication for osteoporosis.
Jiaxuan Li   +5 more
doaj   +3 more sources

Process-Induced Crystal Surface Anisotropy and the Impact on the Powder Properties of Odanacatib [PDF]

open access: yesPharmaceutics
Crystalline active pharmaceutical ingredients with comparable size and surface area can demonstrate surface anisotropy induced during crystallization or downstream unit operations such as milling.
Isha Bade   +7 more
doaj   +3 more sources

Do matrix metalloproteinase and cathepsin K inhibitors work synergistically to reduce dentin erosion? [PDF]

open access: yesJournal of Applied Oral Science, 2023
Objectives To evaluate the effects of matrix metalloproteinase (MMP) and cathepsin K (catK) inhibitors on resistance to dentin erosion. Methodology A total of 96 dentin specimens (3×3×2 mm) were prepared and randomly assigned into four groups (n=24 ...
Xiujiao LIN   +4 more
doaj   +5 more sources

Real-time analysis of osteoclast resorption and fusion dynamics in response to bone resorption inhibitors [PDF]

open access: yesScientific Reports
Cathepsin K (CatK), an essential collagenase in osteoclasts (OCs), is a potential therapeutic target for the treatment of osteoporosis. Using live-cell imaging, we monitored the bone resorptive behaviour of OCs during dose-dependent inhibition of CatK by
Preety Panwar   +5 more
doaj   +4 more sources

Odanacatib Coating Supports Osseointegration of Implants: A Preclinical Study. [PDF]

open access: yesClin Oral Implants Res
Introduction Odanacatib (ODN), a cathepsin K inhibitor, is a drug that reduces bone resorption while preserving bone formation. ODN was initially developed for the treatment of postmenopausal osteoporosis, but further development as a systemic medication
Dos Santos Sanches N   +10 more
europepmc   +2 more sources

CU Cilia – an application for image analysis by machine learning – reveals significance of cysteine cathepsin K activity for primary cilia of human thyroid epithelial cells [PDF]

open access: yesFrontiers in Endocrinology
IntroductionCysteine cathepsins K and L are crucial for proper thyroid function in mice. Inhibition of cysteine peptidases in rodent thyroid epithelial cells in vitro results in loss of primary cilia, highlighting the significance of proteolysis for ...
Maren Rehders   +8 more
doaj   +2 more sources

Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women [PDF]

open access: yesJournal of Osteoporosis, 2010
Osteoclasts are specialized cells that initiate the process of bone resorption, which has two phases, dissolution of the mineral component and degradation of the organic matrix, in which cathepsin K plays a key role.
José Luis Pérez-Castrillón   +4 more
doaj   +4 more sources

Cellular and molecular mechanisms of osteoporosis: current concepts and future direction treatment [PDF]

open access: yesСовременная ревматология, 2016
The article presents review of literature dedicated to the contemporary view on the cellular-molecular mechanisms of the bone remodeling and pathogenesis of the osteoporosis. The discovery of the cytokine RANKL-RANK-OPG system and significant role of the
A. T. Dolzhenko, S. Sagalovsky
doaj   +3 more sources

Varied Bulk Powder Properties of Micro-Sized API within Size Specifications as a Result of Particle Engineering Methods [PDF]

open access: yesPharmaceutics, 2022
Micronized particles are commonly used to improve the content uniformity (CU), dissolution performance, and bioavailability of active pharmaceutical ingredients (API).
Zijian Wang   +6 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy